Pemvidutide

Phase 3Peptide

Pemvidutide is a peptide that works as a Glp-1/glucagon Dual Agonist.[2] It is being investigated across 1 indication, with its most advanced program in Phase 3.[1]

Pemvidutide is one of 5 peptide programs targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 2

1 2

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

1 3

Pemvidutide

Altimmune

Phase 3

1 4

ALN-HSD

Alnylam Pharmaceuticals

Phase 2

1 5

CS060380

CCascade Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Liver

NCT07009860

Q4 2032

Phase 3Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07795164

Clinical

Trials by Indication[1]

Hepatitis1 trial

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Completed· Altimmune logo

Altimmune·Phase 2·NCT05989711·212 enrolled

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting· Altimmune logo

Altimmune·Phase 3·NCT07795164·1,800 enrolled

Liver1 trial

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Active, not recruiting· Altimmune logo

Altimmune·Phase 2·NCT07009860·121 enrolled

Alcohol Use Disorder (AUD)1 trial

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Completed· Altimmune logo

Altimmune·Phase 2·NCT06987513·100 enrolled

Unspecified1 trial

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Completed· Altimmune logo

Altimmune·Phase 1·NCT04972396·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Pemvidutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemvidutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemvidutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glp-1/glucagon Dual Agonist[2]
Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Altimmune

Pemvidutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2032

Trials by Indication[1]

Hepatitis1 trial

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

Liver1 trial

Alcohol Use Disorder (AUD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News